Want to see JP:3750 full AI Analyst Report?

Cytori Cell Research Institute, Inc. (3750) Price & Analysis

1 Followers

3750 Stock Chart & Stats

¥782.00

-¥5.00(-0.59%)

At close: Jan 08 4:00 PM EST

¥782.00

-¥5.00(-0.59%)

Day’s Range― - ―

52-Week Range¥759.00 - ¥890.00

Previous CloseN/A

Volume9.00K

Average Volume (3M)8.33K

Market Cap

¥7.23B

Enterprise Value¥7.13K

Total Cash (Recent Filing)¥67.10M

Total Debt (Recent Filing)¥250.00M

Price to Earnings (P/E)―

Beta0.40

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield1.06%

Share Statistics

EPS (TTM)-62.76

Shares Outstanding8,929,419

10 Day Avg. Volume5,220

30 Day Avg. Volume8,326

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)329.97

Price to Sales (P/S)142.53

P/FCF Ratio-9.26

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Gross Margin RecoveryThe return to positive gross margin indicates that the underlying products or services generated some contribution above direct costs. If sustained, this could provide a base for recovery, although operating expenses currently overwhelm gross profit.

Reported Debt ReductionThe disappearance of reported debt may reduce interest and refinancing pressure and improve financial flexibility. However, the benefit is constrained by the company’s sharply reduced equity base and continuing operating losses.

Reduced Cash Burn Versus Prior YearThe smaller absolute free-cash-flow outflow suggests some improvement in cash consumption compared with the prior year. This is a limited positive because operations remain materially cash-negative and the business is not yet self-funding.

Bears Say

Severe Revenue ContractionThe sustained collapse in revenue indicates substantial deterioration in commercial scale, product demand, or business activity. A smaller revenue base makes it harder to absorb fixed costs and rebuild profitability over the next several periods.

Deep Operating LossesExtremely negative operating and net margins show that overhead and other costs vastly exceed gross profit. Unless the company materially restructures expenses or expands revenue, persistent losses will continue eroding financial resilience.

Weak Balance Sheet And Cash GenerationOngoing cash burn combined with a near-depleted equity cushion leaves limited capacity to absorb further losses. Even with zero reported debt, the company may remain dependent on financing or restructuring to sustain operations.

3750 FAQ

What was Cytori Cell Research Institute, Inc.’s price range in the past 12 months?

Cytori Cell Research Institute, Inc. lowest stock price was ¥759.00 and its highest was ¥890.00 in the past 12 months.

What is Cytori Cell Research Institute, Inc.’s market cap?

Cytori Cell Research Institute, Inc.’s market cap is ¥7.23B.

When is Cytori Cell Research Institute, Inc.’s upcoming earnings report date?

Cytori Cell Research Institute, Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 36 days.

How were Cytori Cell Research Institute, Inc.’s earnings last quarter?

Cytori Cell Research Institute, Inc. released its earnings results on Aug 14, 2026. The company reported -¥10.49 earnings per share for the quarter.

Is Cytori Cell Research Institute, Inc. overvalued?

According to Wall Street analysts Cytori Cell Research Institute, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cytori Cell Research Institute, Inc. pay dividends?

Cytori Cell Research Institute, Inc. pays a Annually dividend of ¥10 which represents an annual dividend yield of 1.06%. See more information on Cytori Cell Research Institute, Inc. dividends here

What is Cytori Cell Research Institute, Inc.’s EPS estimate?

Cytori Cell Research Institute, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cytori Cell Research Institute, Inc. have?

Cytori Cell Research Institute, Inc. has 8,929,419 shares outstanding.

What happened to Cytori Cell Research Institute, Inc.’s price movement after its last earnings report?

Cytori Cell Research Institute, Inc. reported an EPS of -¥10.49 in its last earnings report. Following the earnings report the stock price went down -0.126%.

Which hedge fund is a major shareholder of Cytori Cell Research Institute, Inc.?

Currently, no hedge funds are holding shares in JP:3750

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cytori Cell Research Institute, Inc.

Operating from its Tokyo headquarters, Cytori Cell Research Institute, Inc., established in 2004 (originally FRACTALE Corporation), specializes in the comprehensive research, development, production, and distribution of medical devices related to cell therapy throughout Japan. The company offers various cell therapy kits and continuously advances cellular treatment technologies through ongoing research and development. Its active development pipeline includes ECCI-50, designed for the treatment of male stress urinary incontinence and hepatic cirrhosis, and Cyt-006, formulated to prevent postoperative adhesion after primary rectal cancer surgery. Additionally, Cytori conducts extensive clinical trials and investigations into cell-based therapies for a wide array of conditions and applications, such as the repair of anterior cruciate ligaments and bones, burn scar remediation, chronic wound healing, critical limb ischemia, treatment of anal and Crohn's disease fistulas, and erectile dysfunction. Beyond its primary biotechnological focus, the company also participates in the real estate sector, encompassing investment, ownership, development, leasing, and management of properties and hotels, as well as providing real estate brokerage services.